HK Stock Market Move | METIS TECHBIO-P(07666) rose more than 5%, MTS-128 achieved external authorization, and the company's business model has been market validated.

METIS TECHBIO-P(07666) rose by over 5%, as of the time of writing, it had risen by 5.49%, reaching 11.15 Hong Kong dollars, with a turnover of 31.599 million Hong Kong dollars. On the news front, JiTai Technology previously announced a global exclusive licensing agreement with Boulevard, a company under Deerfield Management, for MTS-128. The company received a $20 million upfront payment, up to $1.6 billion in milestone payments, and potential sales royalties. This is currently the largest-scale authorized transaction in the preclinical stage of TCE projects in China. It is reported that the company, as a leading AI nano-delivery company in China, has successfully validated its business model through platform cooperation and product cooperation. So far, JiTai Technology has over 30 pharmaceutical and biotechnology partners worldwide, including top global pharmaceutical companies, innovative biotechnology companies, and medical research institutions. China Securities Co., Ltd. pointed out in a research report that JiTai Medical's AiProtein platform capabilities are continuously being validated, with the global licensing of MTS-128 marking an important milestone in the company's transition from platform capability construction to commercialization. With NanoForge and AiProtein platforms continuously producing high-quality assets and the dual-drive mode being continuously validated, the firm is optimistic about the company's long-term value in the field of AI-driven protein antibody design and complex therapeutic molecule development.